Patents Examined by Lei Yao
  • Patent number: 11513123
    Abstract: This invention provides methods, reagents, and diagnostic and prognostic markers useful for minimally invasive identification, diagnosis, and therapeutic intervention in individuals with colorectal cancers, or individuals who may be susceptible to developing colorectal cancers.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: November 29, 2022
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Melanie Mae Ivancic, Michael Richard Sussman, William Franklin Dove, Amy Ann Irving, Jennifer Kathleen Pleiman, Edward Lee Huttlin, Xiaodi Chen, Adrian Daniel Hegeman, Mark Reichelderfer, Gregory D. Kennedy, Perry J. Pickhardt
  • Patent number: 11506668
    Abstract: The present invention relates to compositions and methods for cancer therapy, including but not limited to, therapies that utilize cancer biomarkers. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: November 22, 2022
    Inventors: Olav Engebr├ąten, Maria Eb Berstad, Kristian Berg, Anette Weyergang
  • Patent number: 11499973
    Abstract: Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided. The methods may include obtaining a sample from the subject, determining an expression level of at least one biomarker selected from the group consisting of VEGF-D and PlGF in a sample from the subject, comparing the expression level of the biomarker in the sample to a reference level of the biomarker, and predicting the responsiveness of the cancer to treatment with the cancer therapy including a VEGF targeting agent. Optionally, the methods may further include administering a VEGF target agent and/or an anticancer or chemotherapy agent to the subject. Additional methods of prognosing and treating a cancer in a subject are also provided.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: November 15, 2022
    Assignee: Duke University
    Inventors: Andrew Nixon, Chris Brady, Yingmiao Liu, Herbert Hurwitz, Kouros Owzar, Alexander Sibley, Chen Jiang, Ace Hatch, Mark Starr
  • Patent number: 11492415
    Abstract: The present invention relates to a polypeptide including an Fc variant produced by substituting a portion of the amino acid sequence of the Fc domain of a human antibody with a different amino acid sequence. The present invention also relates to an antibody including the polypeptide. The Fc variant can find application in a wide range of antibodies and Fc-fusion constructs. In one aspect, the antibody or Fc fusion construct of the present invention is a therapeutic, diagnostic or laboratory reagent, preferably a therapeutic reagent. The Fc variant is suitable for use in the treatment of cancer because its in vivo half-life can be maximized by optimization of the portion of the amino acid sequence. The antibody or Fc fusion construct of the present invention is used to kill target cells that bear a target antigen, for example cancer cells. Alternatively, the antibody or Fc fusion construct of the present invention is used to block, antagonize or agonize a target antigen.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: November 8, 2022
    Assignees: KOOKMIN UNIVERSITY INDUSTRY ACADEMY, OSONG MEDICAL INNOVATION FOUNDATION
    Inventors: Sang Taek Jung, Sanghwan Ko, Tae Gyu Lee, So Young Choi, Soo Han Lee, Myung Ho Sohn, Su Jin Kim, So Ra Park, Jong Shik Park, Ju Hyeon Lim
  • Patent number: 11492401
    Abstract: The present invention relates to antibody-based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives that are capable of binding to and activating human muscle-specific tyrosine protein kinase (MuSK). The present invention further discloses methods of treating neuromuscular conditions using the aforementioned MuSK antibodies.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: November 8, 2022
    Assignees: NEW YORK UNIVERSITY, ARGENX IIP BV
    Inventors: Steven J. Burden, Shohei Koide, Akiko Koide, Nadia Leloup, Julien Oury, Karen Silence, Roeland Vanhauwaert, Christophe Blanchetot
  • Patent number: 11478539
    Abstract: This application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from (a) polypeptides consisting of amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, (b) polypeptides having a sequence identity of 85% or more with the amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, and (c) polypeptides comprising the polypeptides according to (a) or (b) as the partial sequences, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: October 25, 2022
    Assignee: Toray Industries, Inc.
    Inventors: Akira Kurihara, Fumiyoshi Okano
  • Patent number: 11466086
    Abstract: Disclosed is an isolated monoclonal antibody that specifically binds human 4-1BB, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present disclosure further provides a bispecific molecule, and a pharmaceutical composition comprising the antibody or the bispecific molecule, as well as a treatment method using an anti-4-1BB antibody of the disclosure.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: October 11, 2022
    Assignee: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Xiao Huang, Jianming Sun
  • Patent number: 11454630
    Abstract: This document relates to materials and methods for assessing and/or treating subjects (e.g., subjects having autoimmune diseases). For example, materials and methods for determining if a subject (e.g., a human having an autoimmune disease) has one or more antibodies that can be used to identify the subject as having a lower risk of cancer or as having a higher risk of cancer are provided. Materials and methods for treating a subject (e.g., a human) identified as having a higher cancer risk for cancer are also provided.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: September 27, 2022
    Assignee: The Johns Hopkins University
    Inventors: Ami A. Shah, Livia Casciola-Rosen, Antony Rosen, Takeru Igusa, Marikki K. Laiho
  • Patent number: 11447551
    Abstract: Compositions and methods of making isolated binding molecules (e.g. an antibodies) or antigen-binding fragment thereof useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudin18.2, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder are described. Also, described are pharmaceutical formulations comprising the described compositions for the treatment of diseases either as single agent (e.g., naked antibodies) or as adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies), and/or by combination therapies where the anti-claudin18.2 antibodies are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: September 20, 2022
    Assignee: SparX Bioscience Limited
    Inventors: Guidong Zhu, Jingdong Ye, Jingdong Qin, Jichun Ma
  • Patent number: 11447571
    Abstract: The present application is directed to anti-lambda myeloma antigen (LMA) binding proteins, wherein the binding protein is an antibody. Compositions comprising these antibodies and nucleic acids encoding these antibodies are also disclosed. These antibodies, compositions and nucleic acids may be used in the treatment of LMA expressing pathologies.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: September 20, 2022
    Assignee: HAEMALOGIX PTY LTD
    Inventor: Rosanne Dunn
  • Patent number: 11447565
    Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: September 20, 2022
    Assignee: APEIRON BIOLOGICS AG
    Inventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
  • Patent number: 11434277
    Abstract: Disclosed herein are methods for high-throughput screening of a virus-specific neutralizing antibody. According to certain embodiments of the present disclosure, the virus is an influenza virus. Also disclosed herein are the antibodies selected by the high-throughput screening method, and the uses thereof in the prophylaxis and/or treatment of viral infection.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: September 6, 2022
    Assignee: ACADEMIA SINICA
    Inventors: An-Suei Yang, Ing-Chien Chen, Yi-Kai Chiu, Chung-Ming Yu, Cheng-Chung Lee, Chao-Ping Tung, Yueh-Liang Tsou, Yi-Jen Huang, Chia-Lung Lin, Hong-Sen Chen, Hwei-Jiung Wang
  • Patent number: 11419945
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: August 23, 2022
    Assignee: GLAXO GROUP LIMITED
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • Patent number: 11414492
    Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: August 16, 2022
    Assignees: New York University, PureTech Health, LLC
    Inventors: Shohei Koide, George Miller, Akiko Koide, Linxiao Chen, Eric Elenko, Aleksandra Filipovic, Joseph Bolen
  • Patent number: 11414479
    Abstract: The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: August 16, 2022
    Assignee: Adagio Therapeutics, Inc.
    Inventors: Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
  • Patent number: 11406715
    Abstract: Methods of treating patients having HER2-positive, locally advanced or previously untreated metastatic breast cancer having received prior treatment with a taxane using an anti-HER2-maytansinoid conjugate (for example trastuzumab emtansine) are provided.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: August 9, 2022
    Assignee: Genentech, Inc.
    Inventors: Alice Elizabeth Guardino, Meghna Samant, Alexander Strasak, Melanie Smitt, Monika Patre
  • Patent number: 11407840
    Abstract: The present invention relates to certain anti-M(H)DM2/4 antibodies or antigen-binding fragments thereof, pharmaceutical compositions comprising anti-M(H)DM2/4 antibodies or antigen-binding fragments thereof, antibody-drug conjugates comprising anti-M(H)DM2/4 antibodies or antigen-binding fragments thereof bound to a cytotoxic drug, and the use of such antibodies, fragments, compositions and conjugates for treating cancer and/or for preventing metastases. In particular, described herein are certain antibodies or antigen-binding fragments thereof that specifically bind to extracellularly accessible epitopes of M(H)DM2/4 and inhibit tumor growth in vivo, pharmaceutical compositions comprising such antibodies or fragments, antibody-drug conjugates comprising such antibodies or fragments, and the use of such antibodies, fragments, compositions and conjugates for treating cancer or for preventing metastasis.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: August 9, 2022
    Assignee: NomoCan Pharmaceuticals LLC
    Inventors: Ehsun Sarafraz-Yazdi, Brad R. Evans
  • Patent number: 11401319
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: August 2, 2022
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11390686
    Abstract: The disclosure is directed to antibodies and binding fragments thereof that specifically bind HER3. The disclosure is further directed to immunoconjugates comprising the antibodies and binding fragments thereof that specifically bind HER3. The disclosure is also directed to uses of the antibodies, binding fragments thereof and immunoconjugates for detecting HER3-expressing cells and for treating HER3-expressing cancer.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: July 19, 2022
    Assignee: University of Saskatchewan
    Inventors: Bharathikumar Vellalore Maruthachalam, Ayman Elsayed Mohammad, Jianghai Liu, Humphrey Fonge, Kris Barreto, Clarence Ronald Geyer
  • Patent number: 11391738
    Abstract: The disclosure provides methods for resolving an inconclusive cytological assessment of clinically relevant cells in a sample obtained from a patient based on the cytological detection of an antibody binding to a diagnostic protein in the clinically relevant cells in the sample.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: July 19, 2022
    Assignee: Sienna Cancer Diagnostics Ltd
    Inventors: Minesh Lalla, Fabio Turatti, Sharyn Wilson